A business in context

TRAW research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001104659-26-097261

  2. 8-K · Current report

    Report date 2026-08-14 · 0001104659-26-097226 · Items 2.02,7.01,9.01

  3. 8-K · Current report

    Report date 2026-07-29 · 0001104659-26-089220 · Items 3.01

  4. 4 · Ownership change

    Report date 2026-07-09 · 0002018150-26-000003

  5. 4 · Ownership change

    Report date 2026-07-09 · 0002017800-26-000003

  6. 4 · Ownership change

    Report date 2026-07-09 · 0001237419-26-000003

  7. 4 · Ownership change

    Report date 2026-07-09 · 0002125562-26-000005

  8. 4 · Ownership change

    Report date 2026-07-09 · 0002018274-26-000003

  9. 4 · Ownership change

    Report date 2026-07-09 · 0001958857-26-000003

  10. 4 · Ownership change

    Report date 2026-07-09 · 0001813552-26-000004

  11. 4 · Ownership change

    Report date 2026-07-09 · 0001681955-26-000002

  12. 8-K · Current report

    Report date 2026-07-10 · 0001104659-26-082649 · Items 8.01,9.01

  13. 8-K · Current report

    Report date 2026-07-08 · 0001104659-26-082250 · Items 5.02,5.07,9.01

  14. 8-K · Current report

    Report date 2026-06-22 · 0001104659-26-076058 · Items 7.01,9.01

  15. 8-K · Current report

    Report date 2026-06-12 · 0001104659-26-073593 · Items 7.01,9.01

  16. DEF 14A · Proxy statement

    Report date 2026-07-08 · 0001104659-26-067945

  17. 8-K · Current report

    Report date 2026-05-27 · 0001104659-26-066623 · Items 7.01,9.01

  18. 8-K · Current report

    Report date 2026-05-22 · 0001104659-26-066345 · Items 8.01,9.01

  19. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001104659-26-061779

  20. 8-K · Current report

    Report date 2026-05-15 · 0001104659-26-061771 · Items 2.02,7.01,9.01

  21. 10-K/A · Annual report

    Report date 2025-12-31 · 0001104659-26-053041

  22. 10-K · Annual report

    Report date 2025-12-31 · 0001104659-26-043832

  23. 8-K · Current report

    Report date 2026-04-15 · 0001104659-26-043781 · Items 2.02,7.01,9.01

  24. 8-K · Current report

    Report date 2026-04-15 · 0001104659-26-043497 · Items 1.01,3.02,8.01,9.01

  25. 8-K · Current report

    Report date 2026-02-19 · 0001104659-26-017298 · Items 8.01,9.01

  26. 8-K · Current report

    Report date 2026-01-26 · 0001104659-26-006460 · Items 8.01,9.01

  27. 8-K · Current report

    Report date 2026-01-13 · 0001104659-26-003071 · Items 8.01,9.01

  28. 8-K · Current report

    Report date 2025-12-17 · 0001104659-25-121749 · Items 8.01,9.01

  29. 8-K · Current report

    Report date 2025-12-12 · 0001104659-25-121635 · Items 5.02

  30. 8-K · Current report

    Report date 2025-11-21 · 0001104659-25-116962 · Items 5.02,5.07,9.01

  31. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001104659-25-110845

  32. 8-K · Current report

    Report date 2025-11-13 · 0001104659-25-110829 · Items 2.02,7.01,9.01

  33. 8-K · Current report

    Report date 2025-10-12 · 0001104659-25-100455 · Items 5.02

  34. 8-K · Current report

    Report date 2025-10-14 · 0001104659-25-098994 · Items 8.01,9.01

  35. DEF 14A · Proxy statement

    Report date 2025-11-21 · 0001104659-25-097926

  36. 8-K · Current report

    Report date 2025-10-01 · 0001104659-25-096920 · Items 5.02,7.01,9.01

  37. 8-K · Current report

    Report date 2025-09-09 · 0001104659-25-089564 · Items 1.01,2.01,9.01

  38. 8-K · Current report

    Report date 2025-08-18 · 0001104659-25-079454 · Items 7.01,8.01,9.01

  39. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001558370-25-011469

  40. 8-K · Current report

    Report date 2025-08-14 · 0001104659-25-078060 · Items 2.02,7.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 10 transaction rows10AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

10 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-07-09
2026-07-14
Parker Charles NolanA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
90000.00.0
2026-07-09
2026-07-14
Redfield RobertA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
84000.00.0
2026-07-09
2026-07-16
Pauza Charles DavidA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
97000.00.0
2026-07-09
2026-07-15
Savchuk NikolayA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
93000.00.0
2026-07-09
2026-07-14
Clarke TraffordA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
14150.00.0
2026-07-09
2026-07-14
Shoemaker Mary TeresaA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
14150.00.0
2026-07-09
2026-07-14
Dukes Iain D.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
274000.00.0
2026-07-09
2026-07-14
Leaman John HaroldA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
14150.00.0
2026-07-09
2026-07-15
CAUTREELS WERNERA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
14150.00.0
2026-07-09
2026-07-14
STOVER JACK EA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
14150.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001130598Traws Pharma, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • Onconova Therapeutics, Inc. · former SEC name · 2010-03-04 to 2024-04-01
  • ONCONOVA THERAPEUTICS INC · former SEC name · 2003-01-08 to 2009-05-26

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$226.0K$242.7K
2023-12-31$226.0K$249.9K
2022-12-31$226.0K$260.2K
2021-12-31$226.0K$281.0K
2020-12-31$231.0K$300.7K
2019-12-31$2.18M$2.88M
2018-12-31$1.23M$1.65M
2017-12-31$787.0K$1.08M

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗